Stephen L. Huhn's most recent trade in Contineum Therapeutics Inc. - Ordinary Shares - Class A was a trade of 110,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on Jan. 31, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Contineum Therapeutics Inc... | Stephen L. Huhn | CMO & Sr VP, Clinical Dev. | 31 Jan 2025 | 110,000 | 110,000 | - | - | Stock Option (right to buy) | ||
Contineum Therapeutics Inc... | Stephen L. Huhn | CMO & Sr VP, Clinical Dev. | 13 Aug 2024 | 12,800 | 12,800 | - | 1.0 | 12,928 | Class A Common Stock | |
Contineum Therapeutics Inc... | Stephen L. Huhn | CMO & Sr VP, Clinical Dev. | 13 Aug 2024 | 12,800 | 161,394 | - | - | Stock Option (right to buy) | ||
Contineum Therapeutics Inc... | Stephen L. Huhn | CMO & Sr VP, Clinical Dev. | 24 May 2024 | 100,000 | 100,000 | - | - | Stock Option (right to buy) |